Anixa Biosciences, Inc.
ANIX · NASDAQ
7/31/2025 | 4/30/2025 | 1/31/2025 | 10/31/2024 | |
|---|---|---|---|---|
| Market Cap | $99 | $90 | $93 | $112 |
| - Cash | $1 | $2 | $1 | $1 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $98 | $88 | $93 | $111 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$2 | -$3 | -$3 | -$3 |
| % Margin | – | – | – | – |
| Net Income | $0 | -$3 | -$3 | -$3 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.07 | -0.087 | -0.1 | 0.3 |
| % Growth | 19.2% | 13.4% | -133.3% | – |
| Operating Cash Flow | -$2 | -$2 | -$3 | -$1 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$2 | -$2 | -$3 | -$1 |